Insider Selling: BioSyent Inc. (CVE:RX) Insider Sells 65,000 Shares of Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 65,000 shares of the stock in a transaction dated Thursday, April 13th. The shares were sold at an average price of C$7.70, for a total transaction of C$500,500.00.

FAX Capital Corp. also recently made the following trade(s):

• On Friday, November 22nd, FAX Capital Corp. sold 230,800 shares of BioSyent stock. The shares were sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Price Performance

Shares of CVE:RX opened at C$11.52 on Wednesday. The stock’s 50 day moving average price is C$11.06 and its 200 day moving average price is C$10.29. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. The stock has a market cap of C$133.52 million, a price-to-earnings ratio of 19.20 and a beta of 0.93. BioSyent Inc. has a 12 month low of C$8.24 and a 12 month high of C$11.74.

BioSyent (CVE:RX) last announced its earnings results on Monday, August 26th. The company reported C$0.13 earnings per share for the quarter, meeting the consensus estimate of C$0.13. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. The business had revenue of C$8.95 million during the quarter, compared to analysts’ expectations of C$8.80 million. Equities research analysts anticipate that BioSyent Inc. will post 0.6944444 earnings per share for the current fiscal year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.